Glipizide - A review of the pharmacoeconomic implications of the extended-release formulation in Type 2 diabetes mellitus

Sources: Medical literature published in any language since 1983 on glipizide, identified using AdisBase (a proprietary database of Adis International, Auckland, New Zealand) and Medline. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: AdisBase search terms were 'Glipizide' or 'Type-2-diabetes-mellitus' and ('health-economics' or 'pharmacoepidemiology' or 'prescribing' or 'hospitalisation' or 'formularies' or 'drug-utilisation' or 'meta-analysis' or 'therapeutic-substitution' or 'epidemiology'), or 'Glipizide' and 'Type-2-diabetes-mellitus'. Medline search terms were 'Glipizide' or 'Type-2-diabetes-mellitus' and ('economics' or 'health-policy' or 'quality-of-life' or 'models-statistical' or 'health-planning' or 'epidemiology' or 'guideline in pt' or 'practice-guidelines in pt'. Searches were last updated 01 August 2000. Selection: Economic analyses in patients with type 2 diabetes mellitus who received Glipizide Gastrointestinal Therapeutic System. Inclusion of studies was based mainly on the methods section of the trials. Relevant background data on epidemiology and cost of illness are also included.